Remegen | Sustainability Performance
Develops biopharmaceuticals including antibody-drug conjugates.
2008
China
1,001 - 5,000 employees
Biotechnology
$100M - 500M in revenue
$100M - 500M in profitability
Sustainability Ranking & Industry Benchmark
#7322
Overall#293
in China#144
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projectionsAsset manager exclusion
Market cap
Revenue
R&D intensity
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$527.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
37.5%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
16.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.2
▼ 5.0%
0.3
▲ 9.1%
0.5
▲ 15.6%
11.6
2031Powered by illuminem
Exclusions by region
Reveal data for 2 credits
Institutions excluding by region out of total tracked institutions
Excluding institutions
Reveal data for 2 credits
Institution name, type, screener label
Powered by illuminem and CovalenceEnvironmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
30%
Independent Directors
3 out of 10 incl. management
Overall score
69
Environment
62
Social
65
Governance
79
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
